NextCure's SIM0505 Shows Strong Response in Gynecologic Cancers at ASCO 2026
Event summary
- NextCure presented Phase 1 dose escalation data for SIM0505 at ASCO 2026, showing a 55% ORR in gynecologic cancers.
- SIM0505 achieved a 52.9% ORR in ovarian cancer and 66.7% ORR in uterine serous carcinoma (USC).
- The study enrolled 59 heavily pre-treated patients, with favorable safety and tolerability profiles.
- NextCure plans to host a virtual KOL Event on June 2, 2026, to discuss the data.
The big picture
NextCure's positive Phase 1 data for SIM0505 underscores the potential of antibody-drug conjugates in treating aggressive gynecologic cancers. The results position SIM0505 as a promising candidate in a space with significant unmet medical needs, particularly for platinum-resistant ovarian cancer and uterine serous carcinoma. The ongoing dose optimization study and strategic partnership with Simcere Zaiming highlight NextCure's commitment to advancing this therapy globally.
What we're watching
- Clinical Development
- The pace at which NextCure advances SIM0505 into pivotal studies will determine its commercial potential.
- Regulatory Strategy
- Whether the FDA's Fast Track Designation for platinum-resistant ovarian cancer will accelerate approval timelines.
- Market Positioning
- How SIM0505's efficacy and safety data compare to existing and emerging therapies for gynecologic cancers.
Related topics